Grant: CIHR Fellowship
Direct Payment
$100,000.00
AAV-Mediated Inclusion Formation as a Novel Gene Therapy Strategy for the Assessment and Treatment of ALS
FY 2010-11
Summary
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that attacks the motor neurons of the brain and spinal cord of healthy adults. The disease is fatal, leaving patients paralyzed and unable to breath. There is still no known cause for most cases and no effective treatment or cure. One of the major pathological features of ALS is the accumulation of large protein aggregates inside degenerating neurons. Surprisingly, very few studies have examined the effects of aggregation in ALS. This is likely because the role of aggregation remains controversial, with researchers implicating them either as neurotoxic, with harmful effects on normal cellular function, or as neuroprotective, acting as 'sinks' that sequester otherwise harmful proteins. We believe that by studying the role of aggregates during stress and/or disease, we may gain valuable insight into the cause and propagation of ALS. We have previously shown the formation of aggregates can be related to changes in a process known as alternative splicing, whereby a single gene is capable of producing a number of diverse proteins called isoforms. We have found that certain genes undergo splicing to create isoforms capable of self-aggregation. Interestingly, these isoforms are found associated with most aggregates in ALS. Because cells normally dispose of disease-causing proteins by isolating and degrading them, producing isoforms that aggregate and sequester toxic proteins may be an attempt by the neuron to save itself when overwhelmed by disease. Here, we propose a new method to test whether aggregation is beneficial in ALS. Using adeno-associated viral (AAV) vectors to gene deliver aggregate-prone isoforms, before and after the onset of disease in animal models of ALS, we can manipulate the level of aggregation to see if we can slow disease progression. This research may help explain the relevance of protein aggregation in ALS, and, importantly, generate new treatments for the disease.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
214564
Name
Mclean Jesse R
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
AAV-Mediated Inclusion Formation as a Novel Gene Therapy Strategy for the Assessment and Treatment of ALS
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adeno-Associated Viral Vector; Aggregation; Alternative Splicing; Amyotrophic Lateral Sclerosis (Als); Gene Therapy; Intermediate Filament; Motor Neuron; Neurodegeneration; Peripherin; Superoxide Dismutase (Sod1)
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that attacks the motor neurons of the brain and spinal cord of healthy adults. The disease is fatal, leaving patients paralyzed and unable to breath. There is still no known cause for most cases and no effective treatment or cure. One of the major pathological features of ALS is the accumulation of large protein aggregates inside degenerating neurons. Surprisingly, very few studies have examined the effects of aggregation in ALS. This is likely because the role of aggregation remains controversial, with researchers implicating them either as neurotoxic, with harmful effects on normal cellular function, or as neuroprotective, acting as 'sinks' that sequester otherwise harmful proteins. We believe that by studying the role of aggregates during stress and/or disease, we may gain valuable insight into the cause and propagation of ALS. We have previously shown the formation of aggregates can be related to changes in a process known as alternative splicing, whereby a single gene is capable of producing a number of diverse proteins called isoforms. We have found that certain genes undergo splicing to create isoforms capable of self-aggregation. Interestingly, these isoforms are found associated with most aggregates in ALS. Because cells normally dispose of disease-causing proteins by isolating and degrading them, producing isoforms that aggregate and sequester toxic proteins may be an attempt by the neuron to save itself when overwhelmed by disease. Here, we propose a new method to test whether aggregation is beneficial in ALS. Using adeno-associated viral (AAV) vectors to gene deliver aggregate-prone isoforms, before and after the onset of disease in animal models of ALS, we can manipulate the level of aggregation to see if we can slow disease progression. This research may help explain the relevance of protein aggregation in ALS, and, importantly, generate new treatments for the disease.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mclean, Jesse R
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~